Mengyang Di

20PUBLICATIONS
93CO-AUTHORS
Liquid biopsiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 18, 2026
TP53-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes by Treatment Modality: A Multicenter Cohort From 14 US Centers.

|Aug 14, 2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

|Jul 17, 2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

|Nov 21, 2025
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.

Tycel Phillips, Mengyang Di, Taavy A Miller

|Jun 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.

Christina Poh, Jenna M Voutsinas, Mazyar Shadman

|Feb 28, 2025
End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Mengyang Di, Matthew J Maurer, Christopher R Flowers

Pageof 4

Frequent Collaborators

5 joint publications

Mazyar Shadman

5 joint publications

Stephen D Smith

4 joint publications

Adam J Olszewski

4 joint publications

Ryan C Lynch